Safety, Tolerability and Pharmacokinetic Profile of BIA 2-093, a Novel Putative Antiepileptic Agent, during First Administration to Humans

By Almeida L.   Soares-da-Silva P.  

Drugs in R&D, Vol. 4, Iss. 5, 2003-01 ,pp. : 269-284

Adis International

Access to resources Recommend Favorite

Kinetic inhibitory profile of BIA 3-202, a novel fast tight-binding, reversible and competitive catechol-O-methyltransferase inhibitor

By Bonifacio M.J.   Vieira-Coelho M.A.   Soares-da-Silva P.  

European Journal of Pharmacology, Vol. 460, Iss. 2, 2003-01 ,pp. : 163-170

Elsevier

Access to resources Recommend Favorite

BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of l-DOPA to the brain and reduces its O-methylation

By Parada A.   Loureiro A.I.   Vieira-Coelho M.A.   Hainzl D.   Soares-da-Silva P.  

European Journal of Pharmacology, Vol. 420, Iss. 1, 2001-05 ,pp. : 27-32

Elsevier

Access to resources Recommend Favorite

No Influence of Ethnic Origin on the Pharmacokinetics and Pharmacodynamics of Melagatran Following Oral Administration of Ximelagatran, a Novel Oral Direct Thrombin Inhibitor, to Healthy Male Volunteers

By Johansson L.C.   Andersson M.   Fager G.   Gustafsson D.   Eriksson U.G.  

Clinical Pharmacokinetics, Vol. 42, Iss. 5, 2003-01 ,pp. : 475-484

Adis International

Access to resources Recommend Favorite

Comparable Pharmacokinetics and Pharmacodynamics of Melagatran in Japanese and Caucasian Volunteers after Oral Administration of the Direct Thrombin Inhibitor Ximelagatran

By Wernevik Linda C.  

Clinical Pharmacokinetics, Vol. 45, Iss. 1, 2006-01 ,pp. : 85-94

Adis International

Access to resources Recommend Favorite